➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Medtronic
McKesson
Mallinckrodt
McKinsey

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

EVISTA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Evista, and when can generic versions of Evista launch?

Evista is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in EVISTA is raloxifene hydrochloride. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.

Drug patent expirations by year for EVISTA
Drug Prices for EVISTA

See drug prices for EVISTA

Drug Sales Revenue Trends for EVISTA

See drug sales revenues for EVISTA

Recent Clinical Trials for EVISTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalPhase 4
Shanghai Mental Health CenterPhase 4
National Cancer Institute (NCI)Phase 2

See all EVISTA clinical trials

Pharmacology for EVISTA
Paragraph IV (Patent) Challenges for EVISTA
Tradename Dosage Ingredient NDA Submissiondate
EVISTA TABLET;ORAL raloxifene hydrochloride 020815

US Patents and Regulatory Information for EVISTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EVISTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997   Start Trial   Start Trial
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997   Start Trial   Start Trial
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for EVISTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0584952 980044 Netherlands   Start Trial PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001
0584952 1/1999 Austria   Start Trial PRODUCT NAME: RALOXIFEN ODER DESSEN PHARMEZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/98/073/001- EU/1/98/073/004 19980805
0584952 99C0004 Belgium   Start Trial PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Johnson and Johnson
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.